Treatment with Br-MSCs, saroglitazar, or their combination that was initiated 14 days after the induction of pulmonary fibrosis significantly (p < 0.05) reduced SMAD-3 gene expression compared to the BLM-G. Here, SMAD3 is linked to pulmonary fibrosis.